Phenylethylamine in Paranoid Chronic Schizophrenia

Potkin, Steven G.; Karoum, Farouk; Chuang, Lin-Whei; Cannon-Spoor, H. E.; Phillips, I. D. J.; Wyatt, Richard Jed

doi:10.1126/science.504988

Cited by 218 publications

(36 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There has been much discussion about whether PEA has some physiological role. PEA has been related to depression [ 18,19], schizophrenia [20,21 ], and aggressive disorders [22]. PEA also acts on presynaptic dopaminergic nerve terminals and stimulates dopamine release [4,23].…”

Section: Discussionmentioning

confidence: 99%

Plasma .BETA.-phenylethylamine in Parkinson's Disease.

Miura

2000

Kurume Med. J.

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Plasma .BETA.-phenylethylamine in Parkinson's Disease.

Miura

2000

Kurume Med. J.

View full text Add to dashboard Cite

“…1977; Potkin, Karoum, Chuang, Cannon-Spoor, Phillips & Wyatt, 1979). PEA resembles amphetamine in structure and has a similar behavioural profile.…”

mentioning

confidence: 99%

A Pharmacological Analysis of the Hyperactivity Syndrome Induced by Β‐phenylethylamine in the Mouse

Dourish

1982

British J Pharmacology

View full text Add to dashboard Cite

1 The effects of the putative 5-hydroxytryptamine (5-HT) receptor antagonists, methysergide, mianserin and methergoline, the dopamine receptor antagonists, haloperidol, thioridazine and clozapine, and the noradrenaline (NA) receptor antagonists, phentolamine, phenoxybenzamine and propranolol on the behavioural responses of mice to 3-phenylethylamine (PEA, 75 mg/kg) have been examined. 2 PEA produced a syndrome consisting of three distinct phases. The brief initial phase (0-5 min after injection) which consisted of forward walking, sniffing and headweaving, was succeeded by a locomotor depressant phase (5-20min after injection) which consisted of abortive grooming, headweaving, splayed hindlimbs, forepaw padding, sniffing and hyperreactivity, and a late locomotor stimulant phase (20-35min after injection), which was characterized by forward walking, sniffing, hyperreactivity, rearing and licking. 3 Methysergide, mianserin, methergoline, clozapine and propranolol inhibited headweaving and splayed hindlimbs, whereas haloperidol, thioridazine, phentolamine and phenoxybenzamine had no effect on these responses. Forepaw padding was strongly inhibited by methergoline and a high dose of mianserin, and weakly antagonized by methysergide, clozapine, haloperidol and thioridazine. In contrast, padding was mildly potentiated by phenoxybenzamine and phentolamine but strongly potentiated by propranolol. It is proposed that headweaving and splayed hindlimbs are 5-HT-mediated responses whereas forepaw padding also involves 5-HT mechanisms but may be partially due to release of tryptamine. 4 Rearing and licking were inhibited by haloperidol (most strongly), thioridazine and clozapine but potentiated by mianserin, methysergide, propranolol, phenoxybenzamine or phentolamine. Methergoline inhibited licking without affecting rearing. It is suggested that PEA-induced rearing and licking are produced by activation of dopaminergic neurones and inhibited by 5-HT or NA stimulation. 5 Phenoxybenzamine inhibited sniffing and produced backward walking when administered prior to PEA, suggesting mediation by NA of sniffing and an inhibitory influence of NA on backward walking. 6 Clozapine and thioridazine were the most effective antagonists of hyperreactivity and it is proposed that this response is dopamine-mediated. Forward walking was inhibited by high doses of haloperidol or clozapine and potentiated by methergoline, mianserin or methysergide, suggesting that hyperactivity may also be mediated by dopamine but subject to 5-HT inhibition. 7 Abortive grooming was the dominant behavioural component observed after PEA administration and was prevented by all of the antagonists tested which suggests that catecholamine and 5-HT mechanisms may be involved in the expression of this response. 8 Since PEA is an endogenous compound in animals and man, and has been claimed to be present in abnormal amounts in some schizophrenics, PEA-induced behavioural stimulation in mice (which includes the postulated hallucinogenic responses of abortive grooming and ...

show abstract

“…In fact, some of these so-called trace amines have for over 25 years been thought to be associated with affective behavior, 1 paranoid chronic schizophrenia, 2 and depression. 3 , 4 Moreover, specifi c binding sites with unique pharmacology and localization for some tritium-labeled trace amines have been reported.…”

Section: Introductionmentioning

confidence: 99%

Receptors of Mammalian Trace Amines

Lewin

2008

Drug Addiction

View full text Add to dashboard Cite

Phenylethylamine in Paranoid Chronic Schizophrenia

Cited by 218 publications

References 14 publications

Plasma .BETA.-phenylethylamine in Parkinson's Disease.

Plasma .BETA.-phenylethylamine in Parkinson's Disease.

A Pharmacological Analysis of the Hyperactivity Syndrome Induced by Β‐phenylethylamine in the Mouse

Receptors of Mammalian Trace Amines

Contact Info

Product

Resources

About